Children with Down's syndrome have a lower chance of survival from a particular high-risk form of leukaemia (ALL) than children without the disability, new research shows. Researcher Naomi Michels in the Den Boer group: ‘We need to continue the search for targeted therapies and immunotherapy for these children.’
Children with Down's syndrome have a higher risk of developing acute lymphoblastic leukaemia (ALL) than children without this disability. Around five of the 125 children a year with a new diagnosis of ALL in the Princess Máxima Center have Down's syndrome.
Children at higher risk of their cancer coming back usually receive more intensive treatment. But that’s not possible for children with Down's, as they tend to have more side effects from treatment. The syndrome is a genetic disorder, but the possible effect of DNA changes in leukaemia cells in Down's was still unknown.
In a new study, scientists from the Princess Máxima Center and the Erasmus Medical Center compared the effect of therapy in leukaemia patients with and without Down's syndrome.
The international study, involving researchers from the United Kingdom, Germany, Scandinavia and Australia, was published in Lancet Haematology. In the Netherlands, the study was funded by the Princess Máxima Center Foundation and the Children's Oncological Center Rotterdam Foundation.
Treatment equally effective
To account for differences in known risk factors, data from 136 leukaemia patients with Down's syndrome were matched with those from 407 children who did not have Down's syndrome.
The matched ‘duos’ had the same age, ALL subtype, and blood results at diagnosis. That’s how the researchers knew that any differences that remained were linked to Down's syndrome.
Their analysis showed that the levels of leukaemia cells decreased equally well in both groups of children after the first month of treatment. But the scientists discovered an important difference in longer-term outcome between children with and without Down's syndrome in the so-called Ikaros form of ALL.
Increased chance of cancer coming back
A DNA error in the Ikaros gene leads to a more aggressive form of the disease in all children with leukaemia. But children who also had Down's syndrome had an even worse outcome than children without the disability, the researchers found.
Naomi Michels, PhD student in the Den Boer group, also part of the Oncode Institute, was involved in the study. ‘The Ikaros gene mainly increases the risk of cancer coming back,’ she says.
"Children with Down's syndrome and Ikaros ALL were more likely to see their leukaemia return within five years of treatment."
This was the case in 37 per cent of these children, compared with 13 per cent of Ikaros ALL patients who did not have Down's syndrome. In other types of ALL, there was no notable difference between children with and without Down's syndrome.
Fewer side effects
The researchers believe the difference has to do with an interaction between the genetic changes in Down's syndrome and the Ikaros gene. Michels: ‘We need to continue the search for treatments with fewer side effects, such as targeted therapies and forms of immunotherapy, in order to be able to better treat children with Down's syndrome who have this high-risk form of ALL.’
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.